Recombinant Anti-EGFR x Anti-IGF1R Bispecific Antibody (Bi-nanobody) is designed to be expressed as a VHH from anti-EGFR antibody variable domains fused with a VHH from an anti-IGF1R antibody variable domains. It contains a His-tag at the C/N terminus for affinity purification. The BsAb exits as monomer in reducing and non-reducing conditions. This BsAb can bind and inactivate two receptors simultaneously. It is designed for the research of Colorectal cancer; Cervical cancer; Breast cancer; Pancreatic cancer therapy.